Research programme: Alzheimer's disease therapeutics transdermal - Corium International
Latest Information Update: 24 Aug 2023
At a glance
- Originator Corium International
- Class Amines; Antidementias; Organic bridged compounds; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Alzheimer's disease in USA (Transdermal)
- 28 Dec 2018 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Transdermal, Patch)
- 17 Dec 2018 Corium International has been acquired by Gurnet point capital